If at First You Don't Succeed…

Edlin, Mari
June 2011
Pharmaceutical Representative;Jun2011, Vol. 41 Issue 6, p25
The article focuses on the impression that more Health Maintenance Organizations (HMOs) are restricting drug choices to reduce costs in the U.S. It asserts that most of HMO members opt from a closed formulary, a book containing a compilation of pharmaceutical products with their formulas and methods of preparation. Sanofi-Aventis SA's "Managed Care Digest" 2008-2009 data render many of the trends that formularies are adopting which is on a clear trend in pharmacy benefits among health plans.


Related Articles

  • Dronedarone Tablets (Multaq®). Elliott, William T.; Chan, James // Internal Medicine Alert;9/15/2009, Vol. 31 Issue 17, p133 

    The article offers information on the nature, dosage, potential physiological benefits and hazards, and clinical implications of the Dronedarone drug tablets, marketed as Multaq® by Sanofi-Aventis.

  • Auvi-Q.  // MPR - Pediatricians' Edition;Fall/Winter2013, Vol. 24 Issue 2, pA4 

    The article offers brief information on the Auvi-Q sympathomimetic drug from Sanofi Aventis.

  • PCSK9s are hot on the heels of Merck's Vytorin. Weinstein, Deborah // Medical Marketing & Media;Jan2015, Vol. 50 Issue 1, p16 

    The article presents a head-to-head comparative study conducted by Sanofi-Aventis SA and Regeneron on their PCSK9 aliorocumab against Zetia of Merck.

  • Stradling Lawyer Wins for Generics; Appeal Pending. Reed, Vita // Orange County Business Journal;7/11/2005, Vol. 28 Issue 28, p19 

    Presents news briefs related to the health care industry in Orange County, California, as of July 11, 2005. U.S. District Judge Robert Timlin's granting of a summary judgment in favor of Amphastar Pharmaceuticals Inc. a patent case against French drug maker Sanofi-Aventis SA; Physicians' protest...

  • Sanofi announces results of ORIGIN.  // BioSpectrum;Jul2012, Vol. 10 Issue 7, p115 

    The article reports on the announcement of Sanofi-Aventis SA on the results of the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial that assesses the effects of treatment with insulin glargine versus standard care on cardiovascular (CV) outcomes.

  • OTC Pharmaceuticals Industry Profile: Russia.  // OTC Pharmaceuticals Industry Profile: Russia;Dec2006, p1 

    Presents a profile of the OTC Pharmaceuticals industry in Russia. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Drug Watch.  // Formulary;Nov2007, Vol. 42 Issue 11, p656 

    The article presents the newly developed pharmaceutical drugs in treating Alzheimer's disease. The drugs include Lecozotan by Wyeth which is an oral selective seretonin receptor antagonist, Xaliproden by Sanofi-Aventis SA which is a verbal synthetic nonpeptide neurotrophic substance and...

  • ENDOCRINE SYSTEM.  // MPR - Pharmacist's Edition;Spring2011, Vol. 5 Issue 1, p123 

    The article presents several drug prescriptions for various diseases in the endocrine system including Apidra from Sanofi Aventis SA, Diabenese from Pfizer Inc., and Glucovance from Bristol-Myers Squibb Co.

  • MUSCULOSKELETAL DISORDERS.  // MPR - Pharmacist's Edition;Spring2011, Vol. 5 Issue 1, p201 

    The article offers information on several drugs used for treating musculoskeletal disorders including Rifadin from Sanofi-Aventis SA, Ecotrin from GlaxoSmithKline, and Motrin Tablets from Pfizer Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics